期刊
RHEUMATOLOGY
卷 57, 期 7, 页码 1145-1150出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kex361
关键词
axial spondyloarthritis; ankylosing spondylitis; spondyloarthropathy; treatment; TNF; anti-TNF; TNF blocker; interleukin-17; secukinumab; treat-to-target
类别
资金
- AbbVie
- MSD
- Novartis
- Janssen
- Pfizer
After about 15 years of experience with the TNF blockers as the only effective drugs in axial spondyloarthritis patients who fail conventional treatment, for the first time we see now that another targeted therapy, the inhibition of IL-17, is also effective. By indirect comparison of the treatment effect between the two types of drugs, efficacy seems to be on a similar level. This raises quite a few important questions that are related to both pathogenesis and treatment strategies for which the answers are currently largely unknown, but would be of great relevance for optimizing therapies. In this article, we discuss these questions and ways in which such questions could be answered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据